EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Surgical Science Sweden AB (publ) (SUSRF) fair value: what the stock is really worth

As of Sep 25, 2026: fair value of Surgical Science Sweden AB (publ) $3.74, price $5.20, upside -28.1%, quality 59 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · US · Home Sweden

SS Surgical Science Sweden AB (publ) logo Some data Sep 24, 2026

Surgical Science Sweden AB (publ)

SUSRF · US

Overvalued / MonitorQuality is not strong enough to offset the price risk.

!Fair value $3.74 · Overvalued (−28.1%)
!Quality 59/100
✓Healthy Growth (revenue 5y +56.7 %/yr)
!Thin margins · 5.3% net margin (TTM)
✓Low debt · generates free cash flow
!Mixed vs. peers (6/13)
!Narrow moat 34/100
!Evidence only medium, so the estimate is less certain
!Weak on valuation: 10 out of 100
!Weak on past: 5 out of 100
Watch Surgical Science Sweden AB (publ) for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$36.80 $2.84 Fair Value $3.74 May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $2.84 – $36.80 · fair‑value band $2.51 – $5.66 · the $5.20 price screens above the $3.74 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Surgical Science Sweden AB (publ) in your weekly email

Every Wednesday you see whether Surgical Science Sweden AB (publ) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally.

Show more

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.

Stock analysis

Surgical Science Sweden AB (publ) (SUSRF) currently trades at $5.20, while our model-based Fair Value estimate is $3.74, 28.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $5.78 per share, and 7 of the 24 models we run sit above the $5.20 price.

Bear case: the Economic Profit group reads lowest at $1.92, and 17 of the 24 models stay below the price. Evidence for this calculation is medium.

Scenario range: $2.51 (bear) to $5.66 (bull), the price of $5.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Surgical Science Sweden AB (publ) reported revenue of 990M SEK in FY2025 versus 367M SEK in FY2021, a compound +28.2%/yr. Reported net income was 66.7M SEK in FY2025, compounding −6.2%/yr from FY2021.

Key figures

Market cap $265M · P/E ratio 36.4 · P/S ratio 2.45 · EPS (TTM) $0.1100 · Net margin 6.7% · Return on equity 1.2% · Return on assets (EBIT) 2.9% · Revenue (TTM) 975M SEK.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (medium confidence).

What moves the price

The share trades about 46% below its 52-week high and 83% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −28%, SUSRF screens richer than that median.

Fair Value models

Bear $2.51 Fair Value $3.74 Bull $5.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.0832 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF $2.41 $3.09 $5.05 80
Growth DCF $2.31 $3.27 $4.77 78
Owner Earnings $3.83 $6.82 $12.03 74
All 24 models by family
DCF Models
FCF DCF $2.41 $3.09 $5.05 80
Owner Earnings $3.83 $6.82 $12.03 74
5Y Revenue Exit $2.67 $4.13 $7.20 70
5Y EBITDA Exit $3.87 $6.56 $11.84 72
5Y P/E Exit $2.72 $5.10 $8.34 68
10Y Revenue Exit $2.50 $4.64 $6.01 67
10Y EBITDA Exit $3.32 $6.84 $13.11 64
10Y P/E Exit $2.60 $4.73 $8.19 61
Earnings-Based
Graham-Dodd $0.8800 $6.17 $8.66 63
Lynch FV $3.02 $4.31 $5.60 61
PEG = 1.0 $3.02 $4.31 $5.60 57
EPV $1.79 $1.92 $2.02 74
Multiples
P/E Multiple $2.15 $2.86 $3.58 63
P/S Multiple $1.66 $2.21 $2.76 58
P/B Multiple $1.66 $2.21 $2.76 55
EV/EBIT $3.45 $4.35 $5.25 66
EV/EBITDA $4.67 $5.98 $7.29 67
EV/Revenue $2.67 $3.50 $4.33 54
Asset-Based
NCAV (Graham) $4.16 $5.57 $8.32 54
Growth DCF
Growth DCF $2.31 $3.27 $4.77 78
Rev-Margin DCF $2.87 $4.62 $8.26 70
Economic Profit
Residual Income $5.18 $4.67 $4.42 71
ROIC Compounder $1.79 $1.92 $2.02 72
Growth Earnings
Growth-Adj P/E $4.05 $5.78 $7.52 67

Open the full fair value analysis →

Notify me when SUSRF reaches fair value

Put SUSRF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 59/100

Of which business quality 57 · Market factors (momentum, volatility) 46

Profitability 22
Margins and returns on capital today
Quality Growth 45
Are margins and returns improving?
Cashflow 52
Earnings quality: real cash, not paper profit
Fin. Strength 69
Balance sheet, leverage, solvency risk
Investment 99
Disciplined investing over empire-building
Low Volatility 47
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 9
Distance to the 52-week high (market factor)
Net Issuance 81
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+12.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+56.7%
Start year 2020 (pandemic). Over 10 years: +35.9% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+33.5%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
+29.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+29.7%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.5% vs 24.3%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 11%
Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+23.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.8%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in SEK, Sweden: IMF forecast 2.0% a year to 2030, 2.9% from 2016 to 2025) that is about +21.4% a year for the price and +5.7% for the forecasts.
Forecast 2026 (sales)+1.4%
Forecast 2027 (sales)+11.1%
Projected 2028 (sales)+10.0%
Projected 2029 (sales)+8.9%
Projected 2030 (sales)+7.7%

SUSRF screens overvalued: fair value 28% below the price. Compare with Veeva Systems Inc →

Compare Surgical Science Sweden AB (publ) with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 129 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 59 · Above median
Fair Value upside −17.4% · Above median
Profitability
Return on equity (TTM) 1.2% · Below median
Return on assets 1.4% · Above median
Net margin (TTM) 5.3% · Above median
Operating margin (TTM) 0.0% · Below median
Growth and dividend
Revenue growth −6.1% · Bottom 25%
Balance sheet
Debt / equity 0.06× · Above median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/E (TTM) 36.4× · Pricier than median
P/B 0.63× · Cheapest 25%
P/S (TTM) 2.73× · Pricier than median
P/FCF 39.2× · Priciest 25%
EV/EBITDA 16.3× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 0
FUTURE (revenue growth)0 · sector 42
PAST (return on equity)5 · sector 8
HEALTH (low debt)97 · sector 98
DIVIDEND (yield)0 · sector 44

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $278.57 $306.43 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $26.35 $31.41 +19%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Surgical Science Sweden AB (publ) · Fair Value
$3.74 −28%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Surgical Science Sweden AB (publ) Fair Value". https://www.fairvalue-calculator.com/stock/SUSRF

Frequently asked questions

Is Surgical Science Sweden AB (publ) (SUSRF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $3.74 versus the last price from Sep 25, 2026 of $5.20, about −28% upside (overvalued).
What is the fair value of SUSRF?
Our model-based fair value for Surgical Science Sweden AB (publ) is $3.74 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $5.20.
What is the quality score of SUSRF?
Surgical Science Sweden AB (publ) has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Surgical Science Sweden AB (publ) (SUSRF)?
Our model-based price target is the fair value of $3.74 (as of Sep 24, 2026) from 24 valuation models. Cautious scenario $2.51, optimistic scenario $5.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Surgical Science Sweden AB (publ) stock forecast for 2026?
Our models put fair value at $3.74, about −28% upside versus the last price from Sep 25, 2026 of $5.20 (overvalued). Cautious scenario $2.51, optimistic scenario $5.66. The calculation is refreshed regularly with new filings.
What is the revenue of Surgical Science Sweden AB (publ) (SUSRF)?
Surgical Science Sweden AB (publ) reported trailing-twelve-month revenue of about 975M SEK (latest available figure, as of Sep 24, 2026).
What growth is priced into Surgical Science Sweden AB (publ) (SUSRF)?
For today's price to be fair in a discounted-cash-flow model, Surgical Science Sweden AB (publ) would have to grow free cash flow by +23.8 % per year for five years (discount rate 11.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +56.7 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of SUSRF use?
Our models discount Surgical Science Sweden AB (publ) at 11.4 %: a base by market capitalisation (micro), damped by beta 0.58, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Surgical Science Sweden AB (publ) that is +23.8 % per year a year over ten years, using the same discount rate (11.4 %) and the same formula as our fair value.
How much growth has Surgical Science Sweden AB (publ) (SUSRF) delivered so far?
Over the past 5 years revenue at Surgical Science Sweden AB (publ) grew +56.7 % a year. The price currently implies +23.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Surgical Science Sweden AB (publ) (SUSRF) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into Surgical Science Sweden AB (publ) (+23.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Surgical Science Sweden AB (publ) (SUSRF)?
The free-cash-flow yield on the price is 2.55 %: that much free cash flow Surgical Science Sweden AB (publ) produces per unit of market value. When it exceeds the discount rate of our models (11.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Surgical Science Sweden AB (publ) (SUSRF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Surgical Science Sweden AB (publ) it is $3.74 per share (as of Sep 24, 2026), against a price of $5.20. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Surgical Science Sweden AB (publ) stock overvalued or undervalued in 2026?
As of Sep 24, 2026, SUSRF trades above its calculated fair value: price $5.20, fair value $3.74, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SUSRF?
No. The price is what the market pays today ($5.20); the fair value is what the company's own numbers justify ($3.74). For Surgical Science Sweden AB (publ) the two are $1.46 per share apart. That gap is exactly why we show both numbers side by side.
How much is Surgical Science Sweden AB (publ) worth?
The market values Surgical Science Sweden AB (publ) at about $265M (market capitalisation, as of Sep 24, 2026). Per share that is $5.20; our models calculate a fair value of $3.74 per share.
What do the bullish and bearish scenarios say about SUSRF?
Our models span a range for Surgical Science Sweden AB (publ): cautious scenario $2.51, base $3.74, optimistic $5.66 per share (as of Sep 24, 2026, price $5.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of SUSRF?
Surgical Science Sweden AB (publ) trades at a price-to-earnings ratio of 36.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $3.74 is built from several models across several years. Other multiples: P/B 0.6, P/S 2.7, EV/EBITDA 16.3.
How solid is the balance sheet of Surgical Science Sweden AB (publ) (SUSRF)?
Balance-sheet figures for Surgical Science Sweden AB (publ) (as of Sep 24, 2026): return on equity 1.2%, debt of 0.06 per unit of equity. They feed the Quality Score of 59/100, which measures business quality independently of the share price.
How far is SUSRF from its 52-week high?
Surgical Science Sweden AB (publ) trades at $5.20, about 46% below its 52-week high of $9.71 and 83% above the low of $2.84 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $3.74 is for.
Which stocks are comparable to Surgical Science Sweden AB (publ)?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Surgical Science Sweden AB (publ) stock attractive at the current price?
The data as of Sep 24, 2026: price $5.20, calculated fair value $3.74 (−28%), Quality Score 59/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SUSRF calculated?
We run Surgical Science Sweden AB (publ) through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $3.74, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Surgical Science Sweden AB (publ) itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Surgical Science Sweden AB (publ) (SUSRF)?
The latest price we hold is from Sep 25, 2026 and stands at $5.20. Our model-based fair value is $3.74, about −28% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Surgical Science Sweden AB (publ) right now?
Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($2.51 to $5.66) leaves room in how you read the outcome.

Key figures of Surgical Science Sweden AB (publ)

How large is the market capitalisation of Surgical Science Sweden AB (publ) (SUSRF)?
The market capitalisation of Surgical Science Sweden AB (publ) is $265M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Surgical Science Sweden AB (publ) (SUSRF)?
The price-to-sales ratio of Surgical Science Sweden AB (publ) is 2.45 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Surgical Science Sweden AB (publ) (SUSRF)?
Earnings per share at Surgical Science Sweden AB (publ) are $0.1100 (price ÷ EPS = P/E 36.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Surgical Science Sweden AB (publ) (SUSRF)?
The net margin of Surgical Science Sweden AB (publ) is 6.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Surgical Science Sweden AB (publ) (SUSRF)?
The return on equity (ROE) of Surgical Science Sweden AB (publ) is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Surgical Science Sweden AB (publ) (SUSRF)?
On an EBIT basis the return on assets of Surgical Science Sweden AB (publ) is 2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Surgical Science Sweden AB (publ) (SUSRF)?
Revenue at Surgical Science Sweden AB (publ) is growing −6.1% versus a year earlier (3y avg +7.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Surgical Science Sweden AB (publ) (SUSRF)?
Earnings per share at Surgical Science Sweden AB (publ) are growing −43.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Surgical Science Sweden AB (publ) (SUSRF) hold?
Surgical Science Sweden AB (publ) holds more cash than debt, 613M SEK net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Surgical Science Sweden AB (publ) in the live analysis

One click puts Surgical Science Sweden AB (publ) on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.